ThinleChodonThinle Chodon41.7886000000000087.598699999999994021Chodon, Thinle+1 (773) 8346317Research Professorprns:coAuthorOfcoauthor ofprns:emailEncryptedemail addressFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkAnchorTextlink anchor textvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:orcidIdORCID idvivo:personInPositionpositionsvivo:phoneNumberphonePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titleURLLinkvivo:webpagewebpagerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonRadiation and Cellular OncologyObstetrics and Gynecology-Gynecologic OncologyD016219Procedures581700.876812Immunotherapy, AdoptiveChicago60637ILJunkoMatsuzakiJunko Matsuzaki41.7886000000000087.598699999999994019Matsuzaki, Junko0000-0002-2555-1234Research ProfessorTakemasaTsujiTakemasa Tsuji41.7886000000000087.598699999999994020Tsuji, TakemasaResearch Associate Professor1.535080.00611914220research areas1.54620.3069553coauthor of76.62245.7020360similar to1136selected publicationsAuthorship 1452446Authorship 14524810Authorship 1452511Authorship 1452623Authorship 1452632Authorship 14526714Authorship 1452692Authorship 1452713Authorship 14528110Authorship 1452836Authorship 1452856Authorship 1453068Authorship 1453166Authorship 14522910Authorship 1452553Authorship 1452686Authorship 1452807Authorship 14529115Authorship 1452311Authorship 1452362Authorship 14532211Authorship 1453283Authorship 1453203Authorship 1453241Authorship 1453351Authorship 1452428Authorship 1452569Authorship 1452891Authorship 1453005Authorship 1453059Authorship 145312224265152Shi H, Hong A, Kong X, Koya RC, Song C, Moriceau G, Hugo W, Yu CC, Ng C, Chodon T, Scolyer RA, Kefford RF, Ribas A, Long GV, Lo RSCancer discoveryA novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov. 2014 Jan; 4(1):69-79.Cancer Discov2013-11-21T00:00:002013A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.24265155Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RSCancer discoveryAcquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014 Jan; 4(1):80-93.Cancer Discov2013-11-21T00:00:002013Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.20547105Ray S, Chhabra A, Chakraborty NG, Hegde U, Dorsky DI, Chodon T, von Euw E, Comin-Anduix B, Koya RC, Ribas A, Economou JS, Rosenberg SA, Mukherji B, UCLA-CALTECH-CHLA-USC-UCONN Consortium on Translational Program in Engineered ImmunityClinical immunology (Orlando, Fla.)MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro. Clin Immunol. 2010 Sep; 136(3):338-47.Clin Immunol2010-05-23T00:00:002010MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro.26575466Chodon T, Koya RC, Odunsi KImmunological investigationsActive Immunotherapy of Cancer. Immunol Invest. 2015; 44(8):817-36.Immunol Invest2015-01-01T00:00:002015Active Immunotherapy of Cancer.24583799Robert L, Tsoi J, Wang X, Emerson R, Homet B, Chodon T, Mok S, Huang RR, Cochran AJ, Comin-Anduix B, Koya RC, Graeber TG, Robins H, Ribas AClinical cancer research : an official journal of the American Association for Cancer ResearchCTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res. 2014 May 01; 20(9):2424-32.Clin Cancer Res2014-02-28T00:00:002014CTLA4 blockade broadens the peripheral T-cell receptor repertoire.24634374Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJ, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Daniels GA, Mukherji B, Yang L, Zack JA, Kohn DB, Heath JR, Glaspy JA, Witte ON, Baltimore D, Economou JS, Ribas AClinical cancer research : an official journal of the American Association for Cancer ResearchAdoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res. 2014 May 01; 20(9):2457-65.Clin Cancer Res2014-03-14T00:00:002014Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma.11073825Chodon T, Sugihara T, Igawa HH, Funayama E, Furukawa HThe American journal of pathologyKeloid-derived fibroblasts are refractory to Fas-mediated apoptosis and neutralization of autocrine transforming growth factor-beta1 can abrogate this resistance. Am J Pathol. 2000 Nov; 157(5):1661-9.Am J Pathol2000-11-01T00:00:002000Keloid-derived fibroblasts are refractory to Fas-mediated apoptosis and neutralization of autocrine transforming growth factor-beta1 can abrogate this resistance.24795358Wong DJ, Rao A, Avramis E, Matsunaga DR, Komatsubara KM, Atefi MS, Escuin-Ordinas H, Chodon T, Koya RC, Ribas A, Comin-Anduix BCancer immunology researchExposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function. Cancer Immunol Res. 2014 May; 2(5):459-68.Cancer Immunol Res2014-01-30T00:00:002014Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function.21169256Comin-Anduix B, Chodon T, Sazegar H, Matsunaga D, Mock S, Jalil J, Escuin-Ordinas H, Chmielowski B, Koya RC, Ribas AClinical cancer research : an official journal of the American Association for Cancer ResearchThe oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res. 2010 Dec 15; 16(24):6040-8.Clin Cancer Res2010-12-15T00:00:002010The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations.31221207Liu S, Matsuzaki J, Wei L, Tsuji T, Battaglia S, Hu Q, Cortes E, Wong L, Yan L, Long M, Miliotto A, Bateman NW, Lele SB, Chodon T, Koya RC, Yao S, Zhu Q, Conrads TP, Wang J, Maxwell GL, Lugade AA, Odunsi KJournal for immunotherapy of cancerEfficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer. J Immunother Cancer. 2019 06 20; 7(1):156.J Immunother Cancer2019-06-20T00:00:002019Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer.21602800Ma C, Fan R, Ahmad H, Shi Q, Comin-Anduix B, Chodon T, Koya RC, Liu CC, Kwong GA, Radu CG, Ribas A, Heath JRNature medicineA clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells. Nat Med. 2011 Jun; 17(6):738-43.Nat Med2011-05-22T00:00:002011A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells.12459641Furukawa H, Fujita H, Kokubu I, Yamamoto Y, Sasaki S, Chodon T, Okubo Y, Sugihara T, Kuzumaki NMelanoma researchIdentification of a novel gelsolin truncate in the vertical and metastatic phase malignant melanomas. Melanoma Res. 2002 Dec; 12(6):523-8.Melanoma Res2002-12-01T00:00:002002Identification of a novel gelsolin truncate in the vertical and metastatic phase malignant melanomas.19457253von Euw E, Chodon T, Attar N, Jalil J, Koya RC, Comin-Anduix B, Ribas AJournal of translational medicineCTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med. 2009 May 20; 7:35.J Transl Med2009-05-20T00:00:002009CTLA4 blockade increases Th17 cells in patients with metastatic melanoma.21107323Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RSNatureMelanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010 Dec 16; 468(7326):973-7.Nature2010-11-24T00:00:002010Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.22395615Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, Sosman JA, Kefford RF, Long GV, Nelson SF, Ribas A, Lo RSNature communicationsMelanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012 Mar 06; 3:724.Nat Commun2012-03-06T00:00:002012Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.24812408Atefi M, Avramis E, Lassen A, Wong DJ, Robert L, Foulad D, Cerniglia M, Titz B, Chodon T, Graeber TG, Comin-Anduix B, Ribas AClinical cancer research : an official journal of the American Association for Cancer ResearchEffects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res. 2014 Jul 01; 20(13):3446-57.Clin Cancer Res2014-05-08T00:00:002014Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.30626427Matsuzaki J, Tsuji T, Chodon T, Ryan C, Koya RC, Odunsi KJournal for immunotherapy of cancerA rare population of tumor antigen-specific CD4+CD8+ double-positive aß T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells. J Immunother Cancer. 2019 01 09; 7(1):7.J Immunother Cancer2019-01-09T00:00:002019A rare population of tumor antigen-specific CD4+CD8+ double-positive aß T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells.23519018Ma C, Cheung AF, Chodon T, Koya RC, Wu Z, Ng C, Avramis E, Cochran AJ, Witte ON, Baltimore D, Chmielowski B, Economou JS, Comin-Anduix B, Ribas A, Heath JRCancer discoveryMultifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy. Cancer Discov. 2013 Apr; 3(4):418-29.Cancer Discov2013-03-21T00:00:002013Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy.25038231Gschweng EH, McCracken MN, Kaufman ML, Ho M, Hollis RP, Wang X, Saini N, Koya RC, Chodon T, Ribas A, Witte ON, Kohn DBCancer researchHSV-sr39TK positron emission tomography and suicide gene elimination of human hematopoietic stem cells and their progeny in humanized mice. Cancer Res. 2014 Sep 15; 74(18):5173-83.Cancer Res2014-07-18T00:00:002014HSV-sr39TK positron emission tomography and suicide gene elimination of human hematopoietic stem cells and their progeny in humanized mice.29470191Nowicki TS, Escuin-Ordinas H, Avramis E, Chmielowski B, Chodon T, Berent-Maoz B, Wang X, Kaplan-Lefko P, Yang L, Baltimore D, Economou JS, Ribas A, Comin-Anduix BJournal of immunotherapy (Hagerstown, Md. : 1997)Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products. J Immunother. 2018 Jun; 41(5):248-259.J Immunother2018-06-01T00:00:002018Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products.31338822Matsueda S, Chodon T, Koya RCAdvances in experimental medicine and biologyCellular Immunotherapy in the Treatment of Hematopoietic Malignancies. Adv Exp Med Biol. 2019; 1143:217-229.Adv Exp Med Biol2019-01-01T00:00:002019Cellular Immunotherapy in the Treatment of Hematopoietic Malignancies.20842061Tumeh PC, Koya RC, Chodon T, Graham NA, Graeber TG, Comin-Anduix B, Ribas AJournal of immunotherapy (Hagerstown, Md. : 1997)The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy. J Immunother. 2010 Oct; 33(8):759-68.J Immunother2010-10-01T00:00:002010The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy.20856802Comin-Anduix B, Sazegar H, Chodon T, Matsunaga D, Jalil J, von Euw E, Escuin-Ordinas H, Balderas R, Chmielowski B, Gomez-Navarro J, Koya RC, Ribas APloS oneModulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma. PLoS One. 2010 Sep 15; 5(9):e12711.PLoS One2010-09-15T00:00:002010Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma.30390758Chodon T, Lugade AA, Battaglia S, Odunsi KHematology/oncology clinics of North AmericaEmerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer. Hematol Oncol Clin North Am. 2018 12; 32(6):1025-1039.Hematol Oncol Clin North Am2018-10-01T00:00:002018Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer.22693252Koya RC, Mok S, Otte N, Blacketor KJ, Comin-Anduix B, Tumeh PC, Minasyan A, Graham NA, Graeber TG, Chodon T, Ribas ACancer researchBRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res. 2012 Aug 15; 72(16):3928-37.Cancer Res2012-06-12T00:00:002012BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.32925563Faiena I, Comin-Anduix B, Berent-Maoz B, Bot A, Zomorodian N, Sachdeva A, Said J, Cheung-Lau G, Pang J, Macabali M, Chodon T, Wang X, Cabrera P, Kaplan-Lefko P, Chamie K, Belldegrun AS, Pantuck AJ, Drakaki AJournal of immunotherapy (Hagerstown, Md. : 1997)A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell Carcinoma. J Immunother. 2020 Nov/Dec; 43(9):273-282.J Immunother2020-11-01T00:00:002020A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell Carcinoma.26787823Ribas A, Shin DS, Zaretsky J, Frederiksen J, Cornish A, Avramis E, Seja E, Kivork C, Siebert J, Kaplan-Lefko P, Wang X, Chmielowski B, Glaspy JA, Tumeh PC, Chodon T, Pe'er D, Comin-Anduix BCancer immunology researchPD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunol Res. 2016 Mar; 4(3):194-203.Cancer Immunol Res2016-01-19T00:00:002016PD-1 Blockade Expands Intratumoral Memory T Cells.14675177Funayama E, Chodon T, Oyama A, Sugihara TThe Journal of investigative dermatologyKeratinocytes promote proliferation and inhibit apoptosis of the underlying fibroblasts: an important role in the pathogenesis of keloid. J Invest Dermatol. 2003 Dec; 121(6):1326-31.J Invest Dermatol2003-12-01T00:00:002003Keratinocytes promote proliferation and inhibit apoptosis of the underlying fibroblasts: an important role in the pathogenesis of keloid.24167550Ibarrondo FJ, Yang OO, Chodon T, Avramis E, Lee Y, Sazegar H, Jalil J, Chmielowski B, Koya RC, Schmid I, Gomez-Navarro J, Jamieson BD, Ribas A, Comin-Anduix BPloS oneNatural killer T cells in advanced melanoma patients treated with tremelimumab. PLoS One. 2013; 8(10):e76829.PLoS One2013-10-22T00:00:002013Natural killer T cells in advanced melanoma patients treated with tremelimumab.20624956Koya RC, Mok S, Comin-Anduix B, Chodon T, Radu CG, Nishimura MI, Witte ON, Ribas AProceedings of the National Academy of Sciences of the United States of AmericaKinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses. Proc Natl Acad Sci U S A. 2010 Aug 10; 107(32):14286-91.Proc Natl Acad Sci U S A2010-07-12T00:00:002010Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses.23377663Birkhäuser FD, Koya RC, Neufeld C, Rampersaud EN, Lu X, Micewicz ED, Chodon T, Atefi M, Kroeger N, Chandramouli GV, Li G, Said JW, McBride WH, Kabbinavar FF, Ribas A, Pantuck AJ, Belldegrun AS, Riss JJournal of immunotherapy (Hagerstown, Md. : 1997)Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models. J Immunother. 2013 Feb; 36(2):102-11.J Immunother2013-02-01T00:00:002013Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models.RichardKoyaRichard Koya41.7886000000000087.598699999999994022Koya, RichardProfessorD008545Disorders1634540.720246MelanomaD019496Chemicals & Drugs461560.877627Cancer VaccinesAuthorship 1500891034607898Muthuswamy R, McGray AR, Battaglia S, He W, Miliotto A, Eppolito C, Matsuzaki J, Takemasa T, Koya R, Chodon T, Lichty BD, Shrikant P, Odunsi KJournal for immunotherapy of cancerCXCR6 by increasing retention of memory CD8+ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer. J Immunother Cancer. 2021 10; 9(10).J Immunother Cancer2021-10-01T00:00:002021CXCR6 by increasing retention of memory CD8+ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer.Authorship 1536642835294258Odunsi K, Qian F, Lugade AA, Yu H, Geller MA, Fling SP, Kaiser JC, Lacroix AM, D'Amico L, Ramchurren N, Morishima C, Disis ML, Dennis L, Danaher P, Warren S, Nguyen VA, Ravi S, Tsuji T, Rosario S, Zha W, Hutson A, Liu S, Lele S, Zsiros E, McGray AJR, Chiello J, Koya R, Chodon T, Morrison CD, Putluri V, Putluri N, Mager DE, Gunawan R, Cheever MA, Battaglia S, Matsuzaki JScience translational medicineMetabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses. Sci Transl Med. 2022 03 16; 14(636):eabg8402.Sci Transl Med2022-03-16T00:00:002022Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses.Authorship 154152835460379Zangari B, Tsuji T, Matsuzaki J, Mohammadpour H, Eppolito C, Battaglia S, Ito F, Chodon T, Koya R, Robert McGray AJ, Odunsi KCancer immunology, immunotherapy : CIITcf-1 protects anti-tumor TCR-engineered CD8+ T-cells from GzmB mediated self-destruction. Cancer Immunol Immunother. 2022 Dec; 71(12):2881-2898.Cancer Immunol Immunother2022-04-23T00:00:002022Tcf-1 protects anti-tumor TCR-engineered CD8+ T-cells from GzmB mediated self-destruction.Lee AnnHasselbacherLee Ann Hasselbacher41.7886000000000087.598699999999994154Hasselbacher, Lee AnnResearch Assistant Professor35666273Zangari B, Tsuji T, Matsuzaki J, Mohammadpour H, Eppolito C, Battaglia S, Ito F, Chodon T, Koya R, Robert McGray AJ, Odunsi KCancer immunology, immunotherapy : CIICorrection to: Tcf-1 protects anti-tumor TCR-engineered CD8+ T-cells from GzmB mediated self-destruction. Cancer Immunol Immunother. 2022 Dec; 71(12):2899.Cancer Immunol Immunother2022-12-01T00:00:002022Correction to: Tcf-1 protects anti-tumor TCR-engineered CD8+ T-cells from GzmB mediated self-destruction.Authorship 1552458SrideviChallaSridevi Challa41.7886000000000087.598699999999994276Challa, SrideviAssistant Professorhttps://obgyn.uchicago.edu/page/section-gynecologic-oncologyGynecologic Oncology Section - Univ. of Chicagohttps://obgyn.uchicago.edu/Univ. of Chicago OB&GYNhttp://obg.bsd.uchicago.edu/FacultyResearch/lengyellab.htmOvarian Cancer Laboratory in Chicagohttps://www.uchicagomedicine.org/find-a-physician/physician/ernst-lengyelClinical Profilehttps://www.uchicagomedicine.org/conditions-services/obgyn/specialtyOB&GYN Clinical Patient informationD011948Chemicals & Drugs1223710.821927Receptors, Antigen, T-CellD013601Anatomy30511950.618105T-Lymphocytes37463058Chung DJ, Shah N, Wu J, Logan B, Bisharat L, Callander N, Cheloni G, Anderson K, Chodon T, Dhakal B, Devine S, Somaiya Dutt P, Efebera Y, Geller N, Ghiasuddin H, Hematti P, Holmberg L, Howard A, Johnson B, Karagkouni D, Lazarus HM, Malek E, McCarthy P, McKenna D, Mendizabal A, Nooka A, Munshi N, O'Donnell L, Rapoport AP, Reese J, Rosenblatt J, Soiffer R, Stroopinsky D, Uhl L, Vlachos IS, Waller EK, Young JW, Pasquini MC, Avigan DClinical cancer research : an official journal of the American Association for Cancer ResearchRandomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401. Clin Cancer Res. 2023 12 01; 29(23):4784-4796.Clin Cancer Res2023-12-01T00:00:002023Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401.Authorship 1644339MedicinePathologyUniversity of ChicagoSarahAckroydSarah Ackroyd41.7886000000000087.598699999999994420Ackroyd, SarahAssistant ProfessorHanCunHan Cun41.7886000000000087.598699999999994429Cun, HanAssistant ProfessorRaviSalgiaRavi Salgia41.78927490000000-87.601250000000001937Salgia, RaviEmeritus/Emerita, ProfessorErnst RobertLengyel0m5sBaYMHOD5hHlsaUXv9Gq0+s+oErnst Robert Lengyel41.78927490000000-87.601250000000001942Lengyel, Ernst RobertProfessorRalph R.WeichselbaumxXB+DqgWEf/5hHlsaUXv9Gq0+s+oRalph R. Weichselbaum41.78927490000000-87.601250000000002521Weichselbaum, Ralph R.ProfessorThomas F.GajewskiThomas F. Gajewski41.78927490000000-87.60125000000000355Gajewski, Thomas F.ProfessorYusukeNakamuraYusuke Nakamura41.78927490000000-87.60125000000000582Nakamura, YusukeEmeritus/Emerita, ProfessorSudarshanSharmaSudarshan Sharma41.7886000000000087.598699999999994532Sharma, SudarshanClinical Associatetrue1Emeritus/Emerita, ProfessorEmeritus/Emerita, Professortrue1Emeritus/Emerita, ProfessorEmeritus/Emerita, Professortrue1Research ProfessorResearch Professortrue1Research Associate ProfessorResearch Associate Professortrue1Assistant ProfessorAssistant Professortrue1Clinical AssociateClinical Associatetrue1Research ProfessorResearch Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1Research Assistant ProfessorResearch Assistant Professortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1ProfessorProfessor1010